Anne Li 1/1/17
|
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects 1 in 3,000 people. The study results appeared Dec. 29, 2016, in the New England Journal of Medicine.
See original article at: https://www.cancer.gov/news-events/press-releases/2016/selumetinib-shrinks-pediatric-tumors |
Post a comment